PRF1 and neoplasm: Activation of T cells was observed and tumor killing activity was noticed in 6 PDOs by assessing interferon‐gamma (IFNG), granzyme B (GZMB), and perforin‐1 (PRF1) of CD3+TILs, data that is consistent with clinical trials for different cancer types (Figure 4C).